Do analysts recommend BIVI or MIRA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioVie 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 MIRA Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings and valuation, BIVI or MIRA?

MIRA Pharmaceuticals is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioVie N/A N/A -$17.54M -$2.45 N/A MIRA Pharmaceuticals N/A N/A -$10.44M -$1.30 N/A

Is BIVI or MIRA more profitable?

BioVie's return on equity of -101.15% beat MIRA Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets BioVie N/A -101.15% -90.18% MIRA Pharmaceuticals N/A -140.82% -135.01%

Do analysts recommend BIVI or PYRGF?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioVie 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 PyroGenesis Canada 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts recommend GRML or BIVI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Greenland Mines Ltd. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BioVie 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, GRML or BIVI?

Greenland Mines Ltd. Common Stock is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Greenland Mines Ltd. Common Stock N/A N/A -$10.55M -$0.32 N/A BioVie N/A N/A -$17.54M -$2.45 N/A

Is GRML or BIVI more profitable?

BioVie's return on equity of -101.15% beat Greenland Mines Ltd. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets Greenland Mines Ltd. Common Stock N/A -109.40% -98.80% BioVie N/A -101.15% -90.18%

Do analysts recommend TLPH or BIVI?

Talphera currently has a consensus target price of $3.00, suggesting a potential upside of 243.49%. Given Talphera's stronger consensus rating and higher probable upside, equities analysts clearly believe Talphera is more favorable than BioVie. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Talphera 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 BioVie 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, TLPH or BIVI?

Talphera has higher revenue and earnings than BioVie. Talphera is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Talphera $30K 1,510.98 -$14.29M -$0.31 N/A BioVie N/A N/A -$17.54M -$2.45 N/A

Is TLPH or BIVI more profitable?

Talphera's return on equity of -92.98% beat BioVie's return on equity. Company Net Margins Return on Equity Return on Assets Talphera N/A -92.98% -53.22% BioVie N/A -101.15% -90.18%

Do analysts rate BIVI or LTRN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioVie 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lantern Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, BIVI or LTRN?

Lantern Pharma is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioVie N/A N/A -$17.54M -$2.45 N/A Lantern Pharma N/A N/A -$17.12M -$1.45 N/A

Is BIVI or LTRN more profitable?

BioVie's return on equity of -101.15% beat Lantern Pharma's return on equity. Company Net Margins Return on Equity Return on Assets BioVie N/A -101.15% -90.18% Lantern Pharma N/A -198.34% -129.08%

BioVie (BIVI) Competitors

$1.63 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$1.65 +0.02 (+1.23%)

As of 06/12/2026 04:10 PM Eastern

Compare

BIVI vs. MIRA, PYRGF, GRML, TLPH, and LTRN

Should you buy BioVie stock or one of its competitors? MarketBeat compares BioVie with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BioVie include MIRA Pharmaceuticals (MIRA), PyroGenesis Canada (PYRGF), Greenland Mines Ltd. Common Stock (GRML), Talphera (TLPH), and Lantern Pharma (LTRN). These companies are all part of the "pharmaceutical products" industry.

How does BioVie compare to MIRA Pharmaceuticals?

BioVie (NASDAQ:BIVI) and MIRA Pharmaceuticals (NASDAQ:MIRA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation, analyst recommendations and media sentiment.

BioVie has a beta of 0.67, indicating that its stock price is 33% less volatile than the broader market. Comparatively, MIRA Pharmaceuticals has a beta of 1.43, indicating that its stock price is 43% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioVie	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
MIRA Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

4.6% of BioVie shares are held by institutional investors. Comparatively, 35.2% of MIRA Pharmaceuticals shares are held by institutional investors. 0.9% of BioVie shares are held by company insiders. Comparatively, 6.7% of MIRA Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

MIRA Pharmaceuticals is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioVie	N/A	N/A	-$17.54M	-$2.45	N/A
MIRA Pharmaceuticals	N/A	N/A	-$10.44M	-$1.30	N/A

BioVie's return on equity of -101.15% beat MIRA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioVie	N/A	-101.15%	-90.18%
MIRA Pharmaceuticals	N/A	-140.82%	-135.01%

In the previous week, BioVie and BioVie both had 1 articles in the media. BioVie's average media sentiment score of 1.89 beat MIRA Pharmaceuticals' score of 0.94 indicating that BioVie is being referred to more favorably in the media.

Company	Overall Sentiment
BioVie	Very Positive
MIRA Pharmaceuticals	Positive

Summary

MIRA Pharmaceuticals beats BioVie on 7 of the 11 factors compared between the two stocks.

How does BioVie compare to PyroGenesis Canada?

BioVie (NASDAQ:BIVI) and PyroGenesis Canada (NASDAQ:PYRGF) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk.

BioVie has higher earnings, but lower revenue than PyroGenesis Canada. PyroGenesis Canada is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioVie	N/A	N/A	-$17.54M	-$2.45	N/A
PyroGenesis Canada	$9.14M	4.28	-$21.12M	-$0.04	N/A

BioVie has a net margin of 0.00% compared to PyroGenesis Canada's net margin of -115.14%. PyroGenesis Canada's return on equity of 0.00% beat BioVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioVie	N/A	-101.15%	-90.18%
PyroGenesis Canada	-115.14%	N/A	-60.81%

4.6% of BioVie shares are owned by institutional investors. Comparatively, 0.0% of PyroGenesis Canada shares are owned by institutional investors. 0.9% of BioVie shares are owned by company insiders. Comparatively, 47.7% of PyroGenesis Canada shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

BioVie has a beta of 0.67, indicating that its share price is 33% less volatile than the broader market. Comparatively, PyroGenesis Canada has a beta of 0.19, indicating that its share price is 81% less volatile than the broader market.

In the previous week, BioVie and BioVie both had 1 articles in the media. BioVie's average media sentiment score of 1.89 beat PyroGenesis Canada's score of 0.00 indicating that BioVie is being referred to more favorably in the media.

Company	Overall Sentiment
BioVie	Very Positive
PyroGenesis Canada	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioVie	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
PyroGenesis Canada	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

BioVie beats PyroGenesis Canada on 7 of the 12 factors compared between the two stocks.

How does BioVie compare to Greenland Mines Ltd. Common Stock?

Greenland Mines Ltd. Common Stock (NASDAQ:GRML) and BioVie (NASDAQ:BIVI) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

In the previous week, Greenland Mines Ltd. Common Stock had 1 more articles in the media than BioVie. MarketBeat recorded 2 mentions for Greenland Mines Ltd. Common Stock and 1 mentions for BioVie. BioVie's average media sentiment score of 1.89 beat Greenland Mines Ltd. Common Stock's score of 0.93 indicating that BioVie is being referred to more favorably in the news media.

Company	Overall Sentiment
Greenland Mines Ltd. Common Stock	Positive
BioVie	Very Positive

Greenland Mines Ltd. Common Stock is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Greenland Mines Ltd. Common Stock	N/A	N/A	-$10.55M	-$0.32	N/A
BioVie	N/A	N/A	-$17.54M	-$2.45	N/A

Greenland Mines Ltd. Common Stock has a beta of 6.94, meaning that its stock price is 594% more volatile than the broader market. Comparatively, BioVie has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market.

20.1% of Greenland Mines Ltd. Common Stock shares are held by institutional investors. Comparatively, 4.6% of BioVie shares are held by institutional investors. 11.3% of Greenland Mines Ltd. Common Stock shares are held by insiders. Comparatively, 0.9% of BioVie shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

BioVie's return on equity of -101.15% beat Greenland Mines Ltd. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Greenland Mines Ltd. Common Stock	N/A	-109.40%	-98.80%
BioVie	N/A	-101.15%	-90.18%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Greenland Mines Ltd. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioVie	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Greenland Mines Ltd. Common Stock beats BioVie on 6 of the 10 factors compared between the two stocks.

How does BioVie compare to Talphera?

Talphera (NASDAQ:TLPH) and BioVie (NASDAQ:BIVI) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

37.7% of Talphera shares are owned by institutional investors. Comparatively, 4.6% of BioVie shares are owned by institutional investors. 3.5% of Talphera shares are owned by company insiders. Comparatively, 0.9% of BioVie shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Talphera had 5 more articles in the media than BioVie. MarketBeat recorded 6 mentions for Talphera and 1 mentions for BioVie. BioVie's average media sentiment score of 1.89 beat Talphera's score of 1.21 indicating that BioVie is being referred to more favorably in the news media.

Company	Overall Sentiment
Talphera	Positive
BioVie	Very Positive

Talphera has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market. Comparatively, BioVie has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market.

Talphera currently has a consensus target price of $3.00, suggesting a potential upside of 243.49%. Given Talphera's stronger consensus rating and higher probable upside, equities analysts clearly believe Talphera is more favorable than BioVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Talphera	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
BioVie	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Talphera has higher revenue and earnings than BioVie. Talphera is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Talphera	$30K	1,510.98	-$14.29M	-$0.31	N/A
BioVie	N/A	N/A	-$17.54M	-$2.45	N/A

Talphera's return on equity of -92.98% beat BioVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Talphera	N/A	-92.98%	-53.22%
BioVie	N/A	-101.15%	-90.18%

Summary

Talphera beats BioVie on 12 of the 14 factors compared between the two stocks.

How does BioVie compare to Lantern Pharma?

BioVie (NASDAQ:BIVI) and Lantern Pharma (NASDAQ:LTRN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends.

BioVie has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market. Comparatively, Lantern Pharma has a beta of 2.32, suggesting that its stock price is 132% more volatile than the broader market.

Lantern Pharma is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioVie	N/A	N/A	-$17.54M	-$2.45	N/A
Lantern Pharma	N/A	N/A	-$17.12M	-$1.45	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioVie	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lantern Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

4.6% of BioVie shares are owned by institutional investors. Comparatively, 28.6% of Lantern Pharma shares are owned by institutional investors. 0.9% of BioVie shares are owned by company insiders. Comparatively, 8.5% of Lantern Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

BioVie's return on equity of -101.15% beat Lantern Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioVie	N/A	-101.15%	-90.18%
Lantern Pharma	N/A	-198.34%	-129.08%

In the previous week, BioVie and BioVie both had 1 articles in the media. BioVie's average media sentiment score of 1.89 beat Lantern Pharma's score of 1.87 indicating that BioVie is being referred to more favorably in the media.

Company	Overall Sentiment
BioVie	Very Positive
Lantern Pharma	Very Positive

Summary

Lantern Pharma beats BioVie on 5 of the 9 factors compared between the two stocks.

Get BioVie News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BIVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BIVI vs. The Competition

Export

Metric	BioVie	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$12.29M	$2.99B	$6.52B	$12.05B
Dividend Yield	N/A	1.76%	2.67%	5.66%
P/E Ratio	-0.67	18.84	24.00	24.42
Price / Sales	N/A	324.96	514.65	112.54
Price / Cash	N/A	55.88	27.48	37.92
Price / Book	0.16	3.98	10.69	6.82
Net Income	-$17.54M	$75.79M	$3.57B	$337.56M
7 Day Performance	-2.40%	1.57%	0.61%	1.16%
1 Month Performance	24.43%	-0.73%	1.56%	3.16%
1 Year Performance	-85.70%	23.44%	25.44%	30.60%

BioVie Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BIVI BioVie	0.8146 of 5 stars	$1.63 flat	N/A	-85.7%	$12.29M	N/A	N/A	10
MIRA MIRA Pharmaceuticals	0.952 of 5 stars	$1.05 -0.9%	N/A	-22.3%	$44.54M	N/A	N/A	2
PYRGF PyroGenesis Canada	N/A	$0.21 -3.5%	N/A	-45.1%	$43.93M	$9.14M	N/A	90	Gap Down
GRML Greenland Mines Ltd. Common Stock	0.4086 of 5 stars	$0.36 +0.6%	N/A	-81.7%	$43.16M	N/A	N/A	5	Gap Up
TLPH Talphera	3.262 of 5 stars	$0.79 -2.9%	$3.00 +278.5%	+74.7%	$42.35M	$30K	N/A	19	Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BIVI) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioVie (BIVI) Competitors

BIVI vs. MIRA, PYRGF, GRML, TLPH, and LTRN

How does BioVie compare to MIRA Pharmaceuticals?

Summary

How does BioVie compare to PyroGenesis Canada?

Summary

How does BioVie compare to Greenland Mines Ltd. Common Stock?

Summary

How does BioVie compare to Talphera?

Summary

How does BioVie compare to Lantern Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIVI vs. The Competition

BioVie Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioVie (BIVI) Competitors

BIVI vs. MIRA, PYRGF, GRML, TLPH, and LTRN

How does BioVie compare to MIRA Pharmaceuticals?

Which has more risk and volatility, BIVI or MIRA?

Do analysts recommend BIVI or MIRA?

Do insiders & institutionals hold more shares of BIVI or MIRA?

Which has better earnings and valuation, BIVI or MIRA?

Is BIVI or MIRA more profitable?

Does the media refer more to BIVI or MIRA?

Summary

How does BioVie compare to PyroGenesis Canada?

Which has better earnings and valuation, BIVI or PYRGF?

Is BIVI or PYRGF more profitable?

Do insiders and institutionals have more ownership in BIVI or PYRGF?

Which has more volatility & risk, BIVI or PYRGF?

Does the media favor BIVI or PYRGF?

Do analysts recommend BIVI or PYRGF?

Summary

How does BioVie compare to Greenland Mines Ltd. Common Stock?

Does the media prefer GRML or BIVI?

Which has higher earnings and valuation, GRML or BIVI?

Which has more volatility & risk, GRML or BIVI?

Do institutionals & insiders hold more shares of GRML or BIVI?

Is GRML or BIVI more profitable?

Do analysts recommend GRML or BIVI?

Summary

How does BioVie compare to Talphera?

Do insiders & institutionals hold more shares of TLPH or BIVI?

Does the media prefer TLPH or BIVI?

Which has more risk and volatility, TLPH or BIVI?

Do analysts recommend TLPH or BIVI?

Which has stronger valuation and earnings, TLPH or BIVI?

Is TLPH or BIVI more profitable?

Summary

How does BioVie compare to Lantern Pharma?

Which has more risk and volatility, BIVI or LTRN?

Which has higher earnings and valuation, BIVI or LTRN?

Do analysts rate BIVI or LTRN?

Do institutionals and insiders hold more shares of BIVI or LTRN?

Is BIVI or LTRN more profitable?

Does the media favor BIVI or LTRN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIVI vs. The Competition

BioVie Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools